Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» lymphoma
lymphoma
Novartis exec says Kymriah's ready to square off with Bristol Myers' new CAR-T rival Breyanzi
Novartis exec says Kymriah's ready to square off with Bristol Myers' new CAR-T rival Breyanzi
Fierce Pharma
Bristol Myers Squibb
Breyanzi
CAR-T
lymphoma
Novartis
Kymriah
Flag link:
New study points to why CAR-T therapy may fail in some lymphoma patients
New study points to why CAR-T therapy may fail in some lymphoma patients
Fierce Biotech
CAR-T
lymphoma
Flag link:
FDA to decide on TG Therapeutics’ lymphoma drug early next year
FDA to decide on TG Therapeutics’ lymphoma drug early next year
Pharmaforum
TG Therapeutics
FDA
lymphoma
umbralisib
Bristol-Myers Squibb
Roche
Flag link:
Scopus Bio preps trials of gene-silencing immuno-oncology drug
Scopus Bio preps trials of gene-silencing immuno-oncology drug
Pharmaforum
Scopus BioPharma
lymphoma
immuno-oncology
CpG-STAT3siRNA
gene therapy
Flag link:
ASCO: Allogene reports 63% response rate in early trial of off-the-shelf CAR-T in lymphoma
ASCO: Allogene reports 63% response rate in early trial of off-the-shelf CAR-T in lymphoma
Fierce Biotech
Allogene
ASCO 2020
CAR-T
ALLO-501
ALLO-647
lymphoma
Flag link:
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug
Xconomy
Incyte
MorphoSys
lymphoma
tafasitamab
Flag link:
Servier acquires lymphoma drug Pixuvri from CTI BioPharma
Servier acquires lymphoma drug Pixuvri from CTI BioPharma
Pharmaceutical Business Review
Pixuvri
Servier
CTI BioPharma
M&A
lymphoma
Flag link:
Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments
Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments
Yahoo/Reuters
lymphoma
Gilead Siences
Novartis
cell therapies
Kymriah
Yescarta
Flag link:
TG aims for accelerated approval of lymphoma candidate
TG aims for accelerated approval of lymphoma candidate
BioCentury
TG Therapeutics
umbralisib
TGR-1202
lymphoma
Flag link:
ESMO18: Merck’s STING agonist lacks bite on its own
ESMO18: Merck’s STING agonist lacks bite on its own
Fierce Biotech
Merck
STING agonists
MK-1454
Keytruda
solid tumors
lymphoma
Flag link:
AbbVie's stock falls after lymphoma treatment trial data disappoints
AbbVie's stock falls after lymphoma treatment trial data disappoints
Marketwatch
AbbVie
ibrutinib
clinical trials
lymphoma
Flag link:
Common Serious Side-Effect Of CAR T-Cell Therapy May Be Preventable
Common Serious Side-Effect Of CAR T-Cell Therapy May Be Preventable
Forbes
CAR-T
CRS
lymphoma
leukemia
cytokine release syndrome
Flag link:
Hemo-oncology newbie Bayer gears up for copanlisib launch
Hemo-oncology newbie Bayer gears up for copanlisib launch
Fierce Pharma
hemo-oncology
Bayer
drug launches
copanlisib
lymphoma
Flag link:
Two cancer drug prices have already been hiked by 8% this year
Two cancer drug prices have already been hiked by 8% this year
Marketwatch
drug pricing
cancer
Amgen
Blincyto
Teva Pharmaceutical
Treanda
lymphoma
leukemia
Flag link:
Novartis backs Gamida Cell’s $40M raise to fund a looming PhIII study, marketing and manufacturing prep
Novartis backs Gamida Cell’s $40M raise to fund a looming PhIII study, marketing and manufacturing prep
Endpoints
Novartis
Gamida Cell
clinical trials
cell grafts
bone marrow
leukemia
lymphoma
Flag link:
Novartis' CAR-T stacks up to Kite in lymphoma
Novartis' CAR-T stacks up to Kite in lymphoma
BioPharma Dive
Novartis
CAR-T
Kite Pharma
CTL019
axi-cel
lymphoma
Flag link:
Celldex Cancer Drug Shows Good Early Data
Celldex Cancer Drug Shows Good Early Data
Investopedia
Celldex Therapeutics
CDX-1140
lymphoma
Flag link:
Seattle Genetics moves up FDA timeline for cash cow drug Adcetris
Seattle Genetics moves up FDA timeline for cash cow drug Adcetris
Bizjournals.com
Seattle Genetics
FDA
Adcetris
lymphoma
Flag link:
Glimpse of promising lymphoma responses spurs a sharp spike in Epizyme shares
Glimpse of promising lymphoma responses spurs a sharp spike in Epizyme shares
Fierce Biotech
lymphoma
EPZ-6438
Epizyme
Flag link:
JNJ launches PhII lymphoma study for daratumumab
JNJ launches PhII lymphoma study for daratumumab
Fierce Biotech
JNJ
lymphoma
daratumumab
Genmab
non-Hodgkin's lymphoma
Flag link:
Pages
1
2
3
4
next ›
last »